World Health Organization. Antibiotic resistance. 2018. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance. Accessed 6 Feb 2018.
Google Scholar
World Health Organization. Antimicrobial resistance. 2018. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed 14 Feb 2019.
Google Scholar
Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti-Infect Ther. 2008;6:751–63.
Article
PubMed
Google Scholar
Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2014;3:32.
Article
PubMed
PubMed Central
Google Scholar
Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. 2017;12:e189621.
Article
CAS
Google Scholar
Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52:813–21.
Article
CAS
PubMed
Google Scholar
Sipahi OR. Economics of antibiotic resistance. Expert Rev Anti-Infect Ther. 2008;6:523–39.
Article
PubMed
Google Scholar
Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58.
Article
PubMed
PubMed Central
Google Scholar
Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti-Infect Ther. 2013;11:321–31.
Article
CAS
PubMed
Google Scholar
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. 2013. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 6 Feb 2018.
Google Scholar
European Center for Disease Prevention and Control. The bacterial challenge: time to react. 2009. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf. Accessed 3 July 2019.
Google Scholar
European Centers for Disease Control and Prevention. Antimicrobial resistance: trackling the burden in the European Union. 2019. https://www.oecd.org/health/health-systems/AMR-Tackling-the-Burden-in-the-EU-OECD-ECDC-Briefing-Note-2019.pdf. Accessed 4 July 2019.
Google Scholar
The World Bank. Drug-resistant infections: a threat to our economic future. 2017. http://documents.worldbank.org/curated/en/323311493396993758/final-report. Accessed 4 July 2018.
RAND Corporation. Estimating the economic costs of antimicrobial resistance. 2014. https://www.rand.org/randeurope/research/projects/antimicrobial-resistance-costs.html. Accessed 2 Dec 2018.
Google Scholar
World Health Organization. Global action plan on antimicrobial resistance. 2015. https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1. Accessed 12 Feb 2019.
Google Scholar
World Health Organization. Global priority list of antibiotic resistant bacteria to guide research, discovery, and development of new antibiotics. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed 6 Feb 2019.
World Health Organization. Antimicrobial resistance global report on surveillance. 2014. https://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 11 Dec 2018.
Google Scholar
Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:2475067.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti-Infect Ther. 2013;11:297–308.
Article
CAS
PubMed
Google Scholar
Pogue JM, Kaye KS, Cohen DA, Marchaim D. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect. 2015;21:302–12.
Article
CAS
PubMed
Google Scholar
Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96:843–9.
Article
PubMed
Google Scholar
Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF. Resistance among gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015. Braz J Infect Dis. 2017;21:343–8.
Article
PubMed
Google Scholar
Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF. Antimicrobial susceptibility of gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015. J Med Microbiol. 2017;66:61–9.
Article
PubMed
Google Scholar
Organisation for Economic Cooperation and Development. Exchange rates, end of period. 2019. https://stats.oecd.org/index.aspx?queryid=221#. Accessed 15 Feb 2019.
Google Scholar
Organisation for Economic Cooperation and Development. Consumer price indices. 2019. https://stats.oecd.org/index.aspx?queryid=221#. Accessed 15 Feb 2019.
Google Scholar
Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National costs associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin Infect Dis. 2019;68:22–8.
Article
PubMed
Google Scholar
Chen W, Li S, Li H, Zhang S, Liu B, Zhang X, et al. Comparison in prognosis of hospital-acquired pneumonia due to methicillin-resistant and methicillin-sensitive Staphylococcus aureus: analysis of propensity score matching. Chin J Infect Control. 2016;15:299–303.
CAS
Google Scholar
Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48:3258–62.
Article
PubMed
PubMed Central
Google Scholar
Taneja C, Haque N, Oster G, Shorr AF, Zilber S, Kyan PO, et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med. 2010;5:528–34.
Article
PubMed
Google Scholar
Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit care (London, England). 2006;10:R97.
Article
Google Scholar
Itani KM, Merchant S, Lin SJ, Akhras K, Alandete JC, Hatoum HT. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control. 2011;39:42–9.
Article
PubMed
Google Scholar
Li X, Chen Y, Gao W, Ouyang W, Wei J, Wen Z. Epidemiology and outcomes of complicated skin and soft tissue infections among inpatients in southern China from 2008 to 2013. PLoS One. 2016;11:e149960.
Google Scholar
Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection. 2011;39:141–7.
Article
CAS
PubMed
Google Scholar
Branch-Elliman W, Lee GM, Golen TH, Gold HS, Baldini LM, Wright SB. Health and economic burden of post-partum Staphylococcus aureus breast abscess. PLoS One. 2013;8:e73155.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother. 2004;38:1377–82.
Article
PubMed
Google Scholar
de Kraker MEA, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8:e1001104.
Article
PubMed
PubMed Central
Google Scholar
Ott E, Bange FC, Reichardt C, Graf K, Eckstein M, Schwab F, et al. Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2010;76:300–3.
Article
CAS
PubMed
Google Scholar
Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol. 2009;30:453–60.
Article
PubMed
Google Scholar
McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol. 2004;25:425–30.
Article
PubMed
Google Scholar
Thampi N, Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, et al. Multicenter study of health care cost of patients admitted to hospital with Staphylococcus aureus bacteremia: impact of length of stay and intensity of care. Am J Infect Control. 2015;43:739–44.
Article
PubMed
Google Scholar
Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect. 2010;16:722–8.
Article
CAS
PubMed
Google Scholar
Reed SD, Friedman JY, Engemann JJ, Griffiths RI, Anstrom KJ, Kaye KS, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 2005;26:175–83.
Article
PubMed
Google Scholar
Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592–8.
Article
PubMed
Google Scholar
Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One. 2009;4:e8305.
Article
PubMed
PubMed Central
CAS
Google Scholar
Song X, Perencevich E, Campos J, Short BL, Singh N. Clinical and economic impact of methicillin-resistant Staphylococcus aureus colonization or infection on neonates in intensive care units. Infect Control Hosp Epidemiol. 2010;31:177–82.
Article
PubMed
Google Scholar
Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31:365–73.
Article
PubMed
Google Scholar
Nelson RE, Jones M, Liu CF, Samore MH, Evans ME, Graves N, et al. The impact of healthcare-associated methicillin-resistant Staphylococcus aureus infections on post-discharge healthcare costs and utilization. Infect Control Hosp Epidemiol. 2015;36:534–42.
Article
PubMed
Google Scholar
Lee YJ, Chen JZ, Lin HC, Liu HY, Lin SY, Lin HH, et al. Impact of active screening for methicillin-resistant Staphylococcus aureus (MRSA) and decolonization on MRSA infections, mortality and medical cost: a quasi-experimental study in surgical intensive care unit. Crit Care (London, England). 2015;19:143.
Article
Google Scholar
Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ. 2009;10:287–97.
Article
PubMed
Google Scholar
Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al. Reducing time-dependent bias in estimates of the attributable cost of health care-associated methicillin-resistant Staphylococcus aureus infections: a comparison of three estimation strategies. Med Care. 2015;53:827–34.
Article
PubMed
Google Scholar
Xu B, Yuan H, Yang P. Evaluation of economic burden induced by multidrug-resistant bacteria related infections in a tertiary general hospital. Chinese J Exp Clin Infect Dis. 2017;11:455–9.
Google Scholar
Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc. 2003;51:10–6.
Article
PubMed
Google Scholar
Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26:166–74.
Article
PubMed
Google Scholar
Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005;52:113–22.
Article
PubMed
Google Scholar
Kim CJ, Kim HB, Oh MD, Kim Y, Kim A, Oh SH, et al. The burden of nosocomial Staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study. BMC Infect Dis. 2014;14:590.
Article
PubMed
PubMed Central
Google Scholar
Fu J, Chen B, Wang X, Ye Q, Lu Z, Su C, et al. Case-control study of influence of methicillin-resistant Staphylococcus aureus infection on economic losses and length of hospital stay. Chin J Nosocomiol. 2014;24:2363–5.
Google Scholar
Engler-Huesch S, Heister T, Mutters NT, Wolff J, Kaier K. In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital. BMC Health Serv Res. 2018;18:737.
Article
Google Scholar
Butler AM, Olsen MA, Merz LR, Guth RM, Woeltje KF, Camins BC, et al. Attributable costs of Enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol. 2010;31:28–35.
Article
PubMed
PubMed Central
Google Scholar
Ford CD, Lopansri BK, Haydoura S, Snow G, Dascomb KK, Asch J, et al. Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol. 2015;36:47–53.
Article
PubMed
Google Scholar
Kramer TS, Remschmidt C, Werner S, Behnke M, Schwab F, Werner G, et al. The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections. Antimicrob Resist Infect Control. 2018;7:133.
Article
PubMed
PubMed Central
Google Scholar
Cheah AL, Spelman T, Liew D, Peel T, Howden BP, Spelman D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect. 2013;19:E181–9.
Article
CAS
PubMed
Google Scholar
Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay. J Hosp Infect. 2013;85:54–9.
Article
CAS
PubMed
Google Scholar
Adams DJ, Eberly MD, Goudie A, Nylund CM. Rising vancomycin-resistant Enterococcus infections in hospitalized children in the United States. Hosp Pediatr. 2016;6:404–11.
Article
PubMed
Google Scholar
Gearhart M, Martin J, Rudich S, Thomas M, Wetzel D, Solomkin J, et al. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clin Transpl. 2005;19:711–6.
Google Scholar
Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis. 2001;33:445–52.
Article
CAS
PubMed
Google Scholar
Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223–8.
Article
PubMed
Google Scholar
Nguyen GC, Leung W, Weizman AV. Increased risk of vancomycin-resistant Enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2011;17:1338–42.
Article
PubMed
Google Scholar
Jung E, Byun S, Lee H, Moon SY, Lee H. Vancomycin-resistant Enterococcus colonization in the intensive care unit: clinical outcomes and attributable costs of hospitalization. Am J Infect Control. 2014;42:1062–6.
Article
PubMed
Google Scholar
Puchter L, Chaberny IF, Schwab F, Vonberg RP, Bange FC, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control. 2018;7:1.
Article
PubMed
PubMed Central
Google Scholar
Jiang HL, Zhou Z, Wang LS, Fang Y, Li YH, Chu CI. The risk factors, costs, and survival analysis of invasive VRE infections at a medical center in eastern Taiwan. Int J Infect Dis. 2017;54:18–24.
Article
PubMed
Google Scholar
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med. 2002;28:692–7.
Article
PubMed
Google Scholar
Song XY, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol. 2003;24:251–6.
Article
PubMed
Google Scholar
Maslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N, et al. Impact of infection with extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. J Hosp Infect. 2016;92:33–41.
Article
CAS
PubMed
Google Scholar
Hu B, Ye H, Xu Y, Ni Y, Hu Y, Yu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Curr Med Res Opin. 2010;26:1443–9.
Article
PubMed
Google Scholar
MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9:232–8.
Article
PubMed
Google Scholar
Yang Y, Ku C, Lin J, Shang S, Chiu C, Yeh K, et al. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect. 2010;43:194–9.
Article
PubMed
Google Scholar
Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2008;29:671–4.
Article
PubMed
Google Scholar
Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–71.
Article
CAS
PubMed
Google Scholar
Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226–32.
Article
PubMed
Google Scholar
Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007;28:873–6.
Article
PubMed
Google Scholar
Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, et al. Increased costs associated with bloodstream infections caused by multidrug-resistant gram-negative bacteria are due primarily to patients with hospital-acquired infections. Antimicrob Agents Chemother. 2017;61:e01709-16.
Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Predictors of mortality among patients with community-onset infection due to extended-spectrum beta-lactamase producing Escherichia coli in Thailand. Infect Control Hosp Epidemiol. 2008;29:80–2.
Article
PubMed
Google Scholar
Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control. 2007;35:606–12.
Article
PubMed
Google Scholar
Alam MF, Cohen D, Butler C, Dunstan F, Roberts Z, Hillier S, et al. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice. Int J Antimicrob Agents. 2009;33:255–7.
Article
CAS
PubMed
Google Scholar
Esteve-Palau E, Solande G, Sanchez F, Sorli L, Montero M, Gueerri R, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: a matched cohort study. J Infect. 2015;71:667–74.
Article
CAS
PubMed
Google Scholar
Cornejo-Juarez P, Suarez-Cuenca JA, Volkow-Fernandez P, Silva-Sanchez J, Barrios-Camacho H, Najera-Leon E, et al. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer. 2016;24:253–9.
Article
PubMed
Google Scholar
Meng X, Liu S, Duan J, Huang X, Zhou P, Xiong X, et al. Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. BMC Infect Dis. 2017;17:82.
Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum β-lactamase production in cases of Escherichia coli bloodstream infection. J Glob Antimicrob Resist. 2014;2:107–9.
Article
PubMed
Google Scholar
Huang W, Qiao F, Zhang Y, Huang J, Deng Y, Li J, et al. In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae. Clin Infect Dis. 2018;672:S225–30.
Article
Google Scholar
Chen Z, Xu Z, Wu H, Chen L, Gao S, Chen Y. The impact of carbapenem-resistant Pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: a propensity score-matched analysis. Am J Infect Control. 2018;47:677-82.
Article
PubMed
Google Scholar
Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006;27:893–900.
Article
PubMed
Google Scholar
Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med. 2006;119:526-e19.
Article
CAS
Google Scholar
Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122.
Article
PubMed
PubMed Central
Google Scholar
Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010;31:47–53.
Article
PubMed
Google Scholar
Gasink LB, Fishman NO, Nachamkin I, Bilker WB, Lautenbach E. Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 2007;28:1175–80.
Article
PubMed
Google Scholar
Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 2009;30:746–52.
Article
PubMed
Google Scholar
Cui N, Cao B, Liu Y, Liang L, Gu L, Song S. The impact of imipenem-resistant Acinetobacter baumannii infection on clinical outcomes and medical care costs. Chin J Infect Dis. 2012;30:209–14.
Google Scholar
Zhen X, Chen Y, Hu X, Dong P, Gu S, Sheng YY, et al. The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China. Eur J Clin Microbiol Infect Dis. 2017;36:1989–94.
Article
CAS
PubMed
Google Scholar
Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol. 2009;30:1186–92.
Article
PubMed
Google Scholar
Lee H, Lee H. Clinical and economic evaluation of multidrug-resistant Acinetobacter baumannii colonization in the intensive care unit. Infect Chemother. 2016;48:174–80.
Article
PubMed
PubMed Central
Google Scholar
Wu X, Ding L, Wu X. Direct economic loss due to healthcare-associated infection with multidrug resistant Acinetobacter baumannii. Chin J Infect Control. 2018;17:735–8.
Google Scholar
Guo Y, Guo W, Qiu P, He Q, Pan C, Wu C, et al. Study of attributive hospitalized cost and length of stay for hospital acquired infection due to multidrug resistance and none-resistance Acinetobacter baumannii. Chin J Health Stat. 2017;34:378–81.
Google Scholar
Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713–9.
Article
PubMed
Google Scholar
Thatrimontrichai A, Techato C, Dissaneevate S, Janjindamai W, Maneenil G, Kritsaneepaiboon S, et al. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: a case-case-control study. J Infect Chemother. 2016;22:444–9.
Article
PubMed
Google Scholar
Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2007;28:1247–54.
Article
PubMed
Google Scholar
Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004;32:342–4.
Article
PubMed
Google Scholar
Lemos EV, de la Hoz FP, Alvis N, Einarson TR, Quevedo E, Castaneda C, et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin Microbiol Infect. 2014;20:174–80.
Article
CAS
PubMed
Google Scholar
McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61:361–7.
Article
CAS
PubMed
Google Scholar
Llor C, Bjerrum L. Background for different use of antibiotics in different countries. Clin Infect Dis. 2005;40:333.
Article
PubMed
Google Scholar
Asbell PA, Pandit RT, Sanfilippo CM. Antibiotic resistance rates by geographic region among ocular pathogens collected during the ARMOR surveillance study. Ophthalmol Therapy. 2018;7:417–29.
Article
Google Scholar
World Health Organization. Global antimicrobial resistance surveillance system (GLASS) report-early implementation 2016-2017. 2018. https://www.who.int/glass/resources/publications/early-implementation-report/en/. Accessed 5 Mar 2019.
Google Scholar
KPMG. The economic impact of anti-microbial resistance. 2014. https://home.kpmg.com/content/dam/kpmg/pdf/2014/12/amr-report-final.pdf. Accessed 2 Dec 2018.
Google Scholar
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
Article
CAS
PubMed
Google Scholar
Kaye KS, Pogue JM. Infections caused by resistant gram-negative Bacteria: epidemiology and management. Pharmacotherapy. 2015;35:949–62.
Article
CAS
PubMed
Google Scholar
Weinger MB, Slagle J, Jain S, Ordonez N. Retrospective data collection and analytical techniques for patient safety studies. J Biomed Inform. 2003;36:106–19.
Article
PubMed
Google Scholar